There are no prognostic variables indicating how many lines of therapy patients will receive and whether later lines could be effective. Among 420 subjects, joint probabilities for a patient submitted to first-line therapy to receive further lines were: second line, 74.3%; third line, 47.0%; and fourth line, 21.6%. Moreover, 31% of the patients with early progression during first-line therapy experienced a clinical benefit with later lines. Background: The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. Patients and Methods: We retrospectively collected data from 420 consecutive patients with metastatic colorectal cancer at our institution, describing the proportion of patients who received second or later lines of therapy and the chance of a line of treatment being active when the previous line was not. For each line of treatment, we defined clinical benefit as the probability of not having had evidence of disease progression 6 months after the start of chemotherapy. Results: Of the 373 patients with disease progression after first-line chemotherapy (1L), 277 received a second line (2L) (probability of being submitted to a 2L (P(2L)) ¼ 74.3%): 143 (63.3%) of 226 received a 3L (P(3L)), and 56 (45.9%) of 122 were submitted to a 4L (P(4L)). Joint probabilities were: 2L 74.3%, 3L 47.0%, and 4L 21.6%. A total of 298 (71.5%) of 417 patients had a clinical benefit with 1L; 134 (48.6%) of 276 with 2L; 50 (35.2%) of 142 with 3L; and 12 (25.0%) of 48 with 4L. Taking all these data together, 31% of the patients who experienced early progression at 1L had the chance to have a clinical benefit with any further lines. Conclusion: Our study demonstrated that of 4 patients submitted to a 1L, about 3 will receive a 2L, about 2 a 3L, and nearly 1 a 4L. Later lines could be beneficial even though earlier ones were not.
Introduction
Colorectal cancer (CRC) is the second most frequently diagnosed cancer in women and the third in men, representing 12.7% and 13.2% of all cancers worldwide, respectively, with an estimate of more than 690,000 deaths in 2012. 1 In the last 2 decades, the introduction of new and active agents have led to a progressive improvement in the overall survival of patients with metastatic CRC. Median life expectancy of patients treated with 5-fluorouracil and folinic acid, a unique therapy option in the early 1990s, was 14 months. 2 The introduction of irinotecan and oxaliplatin in the last 2 decades led to an improvement in overall survival that reached an average 21 months. 3 Finally, the description of clinical activity of targeted therapies such as bevacizumab, cetuximab, panitumumab, and more recently aflibercept, regorafenib, and ramucirumab raised the median life expectancy to > 30 months (although some of these agents have been introduced into clinical practice only very recently, and others, like ramucirumab, are not yet available in many countries).
The optimal therapeutic strategy is a matter of debate. Whether is better to administer front-line FOLFIRI or FOLFOX, or which targeted therapy (antievascular endothelial growth factor [VEGF] or antieepidermal growth factor receptor [EGFR] ) has to be administered in the first-line setting in the subgroup of patients who are in principle eligible for both has not yet been established. Moreover, the choice of the first-line therapy drives options for subsequent lines. As an example, if a patient receives FOLFIRI as front-line therapy, aflibercept could not be administered as secondline treatment because it is permitted only in patients with oxaliplatin-resistant disease. Some guidelines have recently been proposed, 11 but gray zones remain. In fact, there are no prognostic indicators that may help clinicians in determining how many chemotherapy lines a single patient will be submitted to, and there is not a sufficient degree of certainty whether the same agent (especially biologicals) administered in later lines of therapy could be as effective as those given earlier. On the other hand, it has been demonstrated that the maximal survival advantage is obtained in those patients who had had the chance to receive all the active treatments, 12 although these observations are affected by selection bias, considering that the exposition to higher number of drugs is clearly a time-dependent variable. We collected data from metastatic CRC patients consecutively followed by the same institution from the time of first diagnosis of metastatic disease in a real-life setting. We sought to describe the proportion of patients submitted to second or further lines of chemotherapy, and to learn whether subsequent lines of therapy would result in disease control when the previous line was not beneficial.
Patients and Methods

Study Design
Clinical data and outcomes of all CRC patients treated at our institution were retrieved from our institutional database based on data prospectively collected since 1993. Data between January 1, 2003, and December 31, 2015, from patients who received first-line regimens were then extracted and entered into a new database specifically designed for the present study. The data extracted included patient demographics, performance status according to the Eastern Cooperative Oncology Group, site of primary lesion (right, from cecum to splenic flexure; left, from splenic flexure to rectum), adjuvant treatment, time of first metastasis occurrence (metachronous vs. synchronous), number of metastatic sites at the beginning of first-line treatment, date of chemotherapy start and disease progression for each line of therapy administered, and date of death or last follow-up visit.
The probability for a patient to receive each line of therapy was calculated by dividing the total number of patients submitted to that line by the number of patients who experienced disease progression while receiving the previous line. The relative probabilities were indicated as follows: P(2L) was the probability to receive a second line, P(3L) the probability to receive a third line, and P(4L) the probability to receive a fourth line. Consequently, the joint probability for a patient submitted to first-line therapy to receive a third line was P(2LX3L) ¼ P(2L) P(3L), and the joint probability for a patient to receive a fourth line was P(2LX3LX4L) ¼ P(2L) P(3L) P(4L).
For each line of treatment, we defined clinical benefit as the probability of having not had evidence of disease progression 6 months after the start of chemotherapy.
Statistical Analyses
Differences between proportions were evaluated by the chi-square test with Yates correction, when appropriate. Statistical inferences of nonparametric unpaired parameters were performed with the Wilcoxon test when comparing 2 or with the Kruskal-Wallis test when comparing 3 or more variables. Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. Overall survival was calculated from the date of diagnosis of metastatic disease until death, or censored at the last follow-up visit. For each line of therapy, progression-free survival was calculated from the date of chemotherapy start to the date of progression or death. In case of no progression, patients were censored at the date of last follow-up visit.
All statistical computations were performed by GraphPad Prism 6.0c for Mac OSX (GraphPad Software, La Jolla, CA), SPSS for Windows 22.0 (IBM SPSS, Chicago, IL), and Statistica for Windows 8.0 (StatSoft, Tulsa, OK). 
Results
A total of 420 patients were included in the analysis. Their main characteristics are summarized in Table 1 .
After first-line treatment, 277 (74.3%) of 373 patients with disease progression received a second line (P(2L)). After the second line, 143 (63.3%) of 226 patients with disease progression received a third line (P(3L)). After the third line, 56 (45.9%) of 122 patients with disease progression received a fourth line (P(4L)) ( Table 2) . As a whole, the joint probabilities for a patient who received a first line to receive further lines of therapy were as follows: second line 74.3%, third line 47.0%, and fourth line 21.6%.
The distribution of antineoplastic agents administered in each line is summarized in Table 2 . Fluoropyrimidines were the backbone of the majority of treatments throughout the lines of therapy. As per internal protocol, oxaliplatin was administered mostly in the first-line setting and irinotecan in the second-line setting.
The proportion of patients submitted to each line of therapy did not differ according to the year of administration of the first line (Table 3) . Nor did they differ by tumor characteristics such as site of primary lesion, time of first metastasis occurrence, number of metastatic sites, and administration of adjuvant treatment (Table 4) . Only age was associated with a significantly different chance of receiving further lines: compared to patients aged > 70 years, younger patients more frequently received a second line (77.7% vs. 67.9%, P ¼ .04), a third line (72% vs. 46.1; P ¼ .001), and a fourth line (49.5% vs. 35.5%), even though this latter difference was not statistically significant (P ¼ .18) ( Table 4) .
Overall, the median number of lines received by patients was 2 (range, 1-7 lines). No difference was demonstrated when patients were stratified according to time of administration of first line (P ¼ .31), site of primary lesion (P ¼ .85), time of first metastasis occurrence (P ¼ .07), number of metastatic sites (P ¼ .12), and administration of adjuvant treatment (P ¼ .25). Younger patients received more later lines of therapy (median, 2 lines; range, 1-7 lines) than elderly patients (median, 2 lines; range, 1-5 lines; P ¼ .01).
At the time of data computation, 291 patients had died, with a median overall survival of 24.5 months. Survival outcomes according to patient and tumor characteristics are summarized in Table 5 . Median progression-free survival for the first, second, third, and fourth lines were 9.3, 5.7, 3.7, and 3.7 months, respectively.
As for clinical benefit, defined as progression-free survival longer than 6 months, 298 (71.5%) of 417 patients had a clinical benefit with first-line therapy, 134 (48.6%) of 276 with second-line therapy, 50 (35.2%) of 142 with third-line therapy, and 12 (25.0%) of 48 with fourth-line therapy.
Progression-free survivals longer than 6 months were also recorded in patients without clinical benefit at the previous line (Table 6 ). In particular, nearly one third of the patients who experienced early disease progression while receiving first-line therapy had the chance to have a clinical benefit to at least one further line.
Discussion
Our analysis provides a description of the probability for patients with advanced CRC of receiving multiple lines of treatment in a real-life setting. We also show that the chance of obtaining a clinical benefit is not negligible, even in the third or fourth line, and a clinical benefit may also be obtained in some of those patients who had experienced early failure of previous treatments.
Several panels of experts and scientific societies (National Comprehensive Cancer Network, https://www.nccn.org/; European Society of Medical Oncology, http://www.esmo.org/) 11 have proposed clinical practice guidelines for patients with metastatic CRC, helping clinicians to choose the best treatment option according to the purpose they want to achieve and the line of therapy. Even though these guidelines suggest treatment options up to the third or even the fourth line of therapy, there are no predictive indicators that can discriminate, at the beginning of the sequence, which patients will actually receive further treatment after the failure of first-line therapy. Indeed, the literature about the probability of a patient Colorectal Cancer in a Real-World Scenario submitted to a first line to receive further lines of therapy is scanty, with only anecdotal evidence describing the proportion of patients submitted to each line of therapy. [13] [14] [15] These studies, however, considered data from particular subsets of patients (elderly patients and patients living in rural zones). Moreover, they described the total number of patients submitted to a given line of therapy without weighting proportions according to the reason why the single patient did not receive a further line. In our study, patients were prospectively followed, and those without disease progression at the latest follow-up were not considered when computing the proportion of patients submitted to a particular line of therapy. According to institutional protocols, oxaliplatin-based chemotherapy was the preferred first-line therapy, whereas irinotecan-based chemotherapy was a common choice for second-line treatments. As it has already been demonstrated that the sequence of chemotherapy (FOLFOX as first line and FOLFIRI as second line, or vice versa) does not influence overall outcome, 3 this characteristic does not represent a bias of our study. Interestingly, in the same study exploring the "best" chemotherapy sequence, 3 the proportions of patients submitted to a second line of therapy in the 2 arms were 74.3% and 62.2%, respectively, which is in line with the results of our study.
No difference in the number of lines of therapy was evident when considering the year of first-line administration and several prognostic factors such as site of primary lesion, time of first metastasis appearance, previous adjuvant treatment, and number of metastatic sites. This could be explained by the relatively long natural history of the tumors, demonstrated by the relatively long median overall survival of the entire population (> 24 months), which permitted us Data are expressed as number of patients (number of patients/eligible patients), with eligible patients being those with disease progression while receiving previous line of therapy.
P values were calculated by chi-square test.
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Clinical Colorectal Cancer December 2017 -375 to administer later lines of therapy even to patients with unfavorable prognostic indicators. The unique difference we found concerned elderly patients, who had lower chances of receiving second-and a third-line therapy, probably as a result of the presence of several comorbidities. The similar probabilities of an elderly patient to be submitted to a fourth line could be easily explained by the low number of subjects in each group and by an evident selection bias, as patients who receive a fourth line are those with more indolent disease and favorable general conditions.
Of interest, approximately 25% of patients who did not experience benefit from a line of therapy (ie, disease progression in less than 6 months) responded to one of the chemotherapy lines that followed (Table 6 ). In general, 31% of patients with early progression after firstline therapy experienced benefit from at least one further chemotherapy line. This is in line with the observation reported by Grothey et al in 2004, 12 where maximal survival advantage was demonstrated in patients who received all the active chemotherapy agents. Thus, the results of our study further support treating patients with good performance status even when they experience rapid disease progression while receiving a previous line of therapy.
Conclusions
Our study shows that nearly three quarters of patients with advanced CRC submitted to first-line therapy will receive a second line, approximately 2 of 4 will receive a third line, and only 21% will receive a fourth line. It will be of interest to identify some prognostic indicators to discriminate those patients who will not receive later lines of therapies, along with predictive factors to select patients who may benefit from more aggressive chemotherapy, such as a triplet therapy combined with a biologic agent as front-line therapy.
Clinical Practice Points
There are few studies reporting the probabilities for a patient with advanced CRC and submitted to first-line treatment to receive further lines.
There are no data concerning the potential benefit of a later line of therapy even when an earlier line was not effective, especially in third-and fourth-line settings. We calculated the joint probabilities for a patient to be submitted to a subsequent line of therapy from a sample of 420 patients consecutively followed at a single institution in a real-life scenario. The probability for each line was calculated considering only those patients who experienced disease progression after the previous line. Joint probabilities to be submitted to further lines were as follows: second line, 74.3%; third line, 47.0%; fourth line, 21.6%. As a whole, 31% of the patients who experienced early disease progression at first-line therapy had the chance to have a clinical benefit with any of the further lines. Half of the patients submitted to first-line therapy are submitted to a third line; this ought to be taken into account when planning new trials in this patient setting.
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